gms | German Medical Science

57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

German Society for Neuropathology and Neuroanatomy

12. - 15.09.2012, Erlangen

57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

Article

Send article

Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model

Meeting Abstract

Search Medline for

  • presenting/speaker Patrick N. Harter - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Stephan Dützmann - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Ulrich Drott - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Elke Hattingen - Department of Neuroradiology, Goethe University Frankfurt, Frankfurt, Germany
  • David Capper - Institute of Neuropathology, Heidelberg, Germany; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Florian Gessler - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Christian Senft - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Volker Seifert - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Karl-Heinz Plate - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany
  • Donat Kögel - Experimental Neurosurgery, Center for Neurology and Neurosurgery, Frankfurt, Germany
  • Michel Mittelbronn - Goethe University Frankfurt, Edinger Institute (Neurological Institute), Frankfurt, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP5.9

doi: 10.3205/12dgnn109, urn:nbn:de:0183-12dgnn1095

Published: September 11, 2012

© 2012 Harter et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

In vitro and descriptive studies of human tissue samples revealed the pro-coagulant glycoprotein tissue factor (TF) as a potent player in glioma cell infiltration that is activated by hypoxia and has also been shown to be upregulated by mutations of TP53 or PTEN. In the present study, we established a murine xenograft treatment model by transplanting the angiogenic and diffusely infiltrating human glioma cell line MZ-18 with endogenous TF expression into nude mice brains and treating these mice with a novel intracranial osmotic pump system continuously infusing a monoclonal antibody against TF (mAb TF9-10H10). The human MZ-18 cell line harbours two homozygous TP53 mutations resulting in a strong nuclear accumulation of p53 thereby facilitating the unambiguous identification of tumor cells in the xenograft model. Intracranial application of TF9-10H10 significantly reduced invasion of MZ-18 cells compared to mock treated control animals. The extent of activated blood vessels was also reduced upon anti-TF treatment. In conclusion, targeting the tissue factor pathway might be a promising treatment strategy for future glioblastoma therapies.